AZD-9291 | Ozymertynib | Mereletynib CAS 1421373-65-0 AZD9291 lung cancer Treatment Active Pharma Ingredient Sales Contacts. Anticancer drug research chemical use only for sale. AZD-9291 Purity 99% available
AZD-9291 | Ozymertynib | Mereletynib CAS 1421373-65-0
AZD-9291
Inne nazwy: N(2{[2(diMethylaMino)etyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}fenyl)prop2enaMide;N-[2-[[2-(Dimethylamino)etyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]fenyl]-2-propenamide;AZD9291,AZD-9291
CAS: 1421373-65-0
MF: C28H33N7O2
MW: 499.61 .
AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 oraz 16.2 μM, odpowiednio). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.
